Effect of weight reductions on estimated kidney function: Post-hoc analysis of two randomized trials

Bernt Johan von Scholten; Melanie J Davies; Frederik Persson; Tine W Hansen; Sten Madsbad; Lars Endahl; Cecilie H Jepsen; Peter Rossing

doi:10.1016/j.jdiacomp.2017.04.003

Effect of weight reductions on estimated kidney function: Post-hoc analysis of two randomized trials

Bernt Johan von Scholten, Melanie J Davies, Frederik Persson, Tine W Hansen, Sten Madsbad, Lars Endahl, Cecilie H Jepsen, Peter Rossing

Department of Clinical Medicine

2 Citations (Scopus)

Abstract

AIMS: Weight loss-induced serum creatinine reduction may increase creatinine-based estimated glomerular filtration rate (eGFR) producing incorrect estimates of kidney function. We investigated whether weight changes in the SCALE program with liraglutide 3.0mg were associated with changes in serum creatinine.

METHODS: Post hoc analysis of two 56-week, randomized, double-blind trials: SCALE Obesity and Prediabetes (n=3731, without type 2 diabetes [T2D], randomized [2:1] to liraglutide 3.0mg [n=2487] or placebo [n=1244]); SCALE Diabetes (n=846 with T2D, randomized [2:1:1] to liraglutide 3.0mg [n=423], 1.8mg [n=211, excluded from this analysis] or placebo [n=212]). NCT01272219/NCT01272232.

RESULTS: In SCALE Obesity and Prediabetes, mean (±SD) weight loss (baseline to week 56) with liraglutide was 8.0±6.7% (2.6±6.9% with placebo); baseline creatinine with liraglutide was 76±15μmol/L and 74±15μmol/L after 56weeks (similar across treatment groups). In SCALE Diabetes, weight loss with liraglutide was 5.9±5.5% (2.0±4.3% with placebo); baseline creatinine was 79±19μmol/L (77±16μmol/L, placebo) and 79±20μmol/L after 56weeks (76±15μmol/L, placebo). No association between changes in weight and changes in serum creatinine was observed (P≥0.05, both trials, all tests).

CONCLUSIONS: Moderate gradual body weight reductions observed in the SCALE program were not associated with changes in serum creatinine.

Original language	English
Journal	Journal of Diabetes and its Complications
Volume	31
Issue number	7
Pages (from-to)	1164-1168
ISSN	1056-8727
DOIs	https://doi.org/10.1016/j.jdiacomp.2017.04.003
Publication status	Published - Jul 2017

Keywords

Adult
Anti-Obesity Agents/adverse effects
Biomarkers/blood
Body Mass Index
Combined Modality Therapy/adverse effects
Creatinine/blood
Diabetes Mellitus, Type 2/blood
Diabetic Nephropathies/chemically induced
Double-Blind Method
Female
Glomerular Filtration Rate/drug effects
Glycated Hemoglobin A/analysis
Humans
Hypoglycemic Agents/adverse effects
Kidney/drug effects
Liraglutide/adverse effects
Male
Middle Aged
Obesity/complications
Prediabetic State/blood
Renal Insufficiency/chemically induced
Weight Loss/drug effects

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1016/j.jdiacomp.2017.04.003

Cite this

@article{8a6c8df8ddf040229122410632e73139,

title = "Effect of weight reductions on estimated kidney function: Post-hoc analysis of two randomized trials",

abstract = "AIMS: Weight loss-induced serum creatinine reduction may increase creatinine-based estimated glomerular filtration rate (eGFR) producing incorrect estimates of kidney function. We investigated whether weight changes in the SCALE program with liraglutide 3.0mg were associated with changes in serum creatinine.METHODS: Post hoc analysis of two 56-week, randomized, double-blind trials: SCALE Obesity and Prediabetes (n=3731, without type 2 diabetes [T2D], randomized [2:1] to liraglutide 3.0mg [n=2487] or placebo [n=1244]); SCALE Diabetes (n=846 with T2D, randomized [2:1:1] to liraglutide 3.0mg [n=423], 1.8mg [n=211, excluded from this analysis] or placebo [n=212]). NCT01272219/NCT01272232.RESULTS: In SCALE Obesity and Prediabetes, mean (±SD) weight loss (baseline to week 56) with liraglutide was 8.0±6.7% (2.6±6.9% with placebo); baseline creatinine with liraglutide was 76±15μmol/L and 74±15μmol/L after 56weeks (similar across treatment groups). In SCALE Diabetes, weight loss with liraglutide was 5.9±5.5% (2.0±4.3% with placebo); baseline creatinine was 79±19μmol/L (77±16μmol/L, placebo) and 79±20μmol/L after 56weeks (76±15μmol/L, placebo). No association between changes in weight and changes in serum creatinine was observed (P≥0.05, both trials, all tests).CONCLUSIONS: Moderate gradual body weight reductions observed in the SCALE program were not associated with changes in serum creatinine.",

keywords = "Adult, Anti-Obesity Agents/adverse effects, Biomarkers/blood, Body Mass Index, Combined Modality Therapy/adverse effects, Creatinine/blood, Diabetes Mellitus, Type 2/blood, Diabetic Nephropathies/chemically induced, Double-Blind Method, Female, Glomerular Filtration Rate/drug effects, Glycated Hemoglobin A/analysis, Humans, Hypoglycemic Agents/adverse effects, Kidney/drug effects, Liraglutide/adverse effects, Male, Middle Aged, Obesity/complications, Prediabetic State/blood, Renal Insufficiency/chemically induced, Weight Loss/drug effects",

author = "{von Scholten}, {Bernt Johan} and Davies, {Melanie J} and Frederik Persson and Hansen, {Tine W} and Sten Madsbad and Lars Endahl and Jepsen, {Cecilie H} and Peter Rossing",

year = "2017",

month = jul,

doi = "10.1016/j.jdiacomp.2017.04.003",

language = "English",

volume = "31",

pages = "1164--1168",

journal = "Journal of Diabetes and its Complications",

issn = "1056-8727",

publisher = "Elsevier",

number = "7",

}

TY - JOUR

T1 - Effect of weight reductions on estimated kidney function

T2 - Post-hoc analysis of two randomized trials

AU - von Scholten, Bernt Johan

AU - Davies, Melanie J

AU - Persson, Frederik

AU - Hansen, Tine W

AU - Madsbad, Sten

AU - Endahl, Lars

AU - Jepsen, Cecilie H

AU - Rossing, Peter

PY - 2017/7

Y1 - 2017/7

N2 - AIMS: Weight loss-induced serum creatinine reduction may increase creatinine-based estimated glomerular filtration rate (eGFR) producing incorrect estimates of kidney function. We investigated whether weight changes in the SCALE program with liraglutide 3.0mg were associated with changes in serum creatinine.METHODS: Post hoc analysis of two 56-week, randomized, double-blind trials: SCALE Obesity and Prediabetes (n=3731, without type 2 diabetes [T2D], randomized [2:1] to liraglutide 3.0mg [n=2487] or placebo [n=1244]); SCALE Diabetes (n=846 with T2D, randomized [2:1:1] to liraglutide 3.0mg [n=423], 1.8mg [n=211, excluded from this analysis] or placebo [n=212]). NCT01272219/NCT01272232.RESULTS: In SCALE Obesity and Prediabetes, mean (±SD) weight loss (baseline to week 56) with liraglutide was 8.0±6.7% (2.6±6.9% with placebo); baseline creatinine with liraglutide was 76±15μmol/L and 74±15μmol/L after 56weeks (similar across treatment groups). In SCALE Diabetes, weight loss with liraglutide was 5.9±5.5% (2.0±4.3% with placebo); baseline creatinine was 79±19μmol/L (77±16μmol/L, placebo) and 79±20μmol/L after 56weeks (76±15μmol/L, placebo). No association between changes in weight and changes in serum creatinine was observed (P≥0.05, both trials, all tests).CONCLUSIONS: Moderate gradual body weight reductions observed in the SCALE program were not associated with changes in serum creatinine.

AB - AIMS: Weight loss-induced serum creatinine reduction may increase creatinine-based estimated glomerular filtration rate (eGFR) producing incorrect estimates of kidney function. We investigated whether weight changes in the SCALE program with liraglutide 3.0mg were associated with changes in serum creatinine.METHODS: Post hoc analysis of two 56-week, randomized, double-blind trials: SCALE Obesity and Prediabetes (n=3731, without type 2 diabetes [T2D], randomized [2:1] to liraglutide 3.0mg [n=2487] or placebo [n=1244]); SCALE Diabetes (n=846 with T2D, randomized [2:1:1] to liraglutide 3.0mg [n=423], 1.8mg [n=211, excluded from this analysis] or placebo [n=212]). NCT01272219/NCT01272232.RESULTS: In SCALE Obesity and Prediabetes, mean (±SD) weight loss (baseline to week 56) with liraglutide was 8.0±6.7% (2.6±6.9% with placebo); baseline creatinine with liraglutide was 76±15μmol/L and 74±15μmol/L after 56weeks (similar across treatment groups). In SCALE Diabetes, weight loss with liraglutide was 5.9±5.5% (2.0±4.3% with placebo); baseline creatinine was 79±19μmol/L (77±16μmol/L, placebo) and 79±20μmol/L after 56weeks (76±15μmol/L, placebo). No association between changes in weight and changes in serum creatinine was observed (P≥0.05, both trials, all tests).CONCLUSIONS: Moderate gradual body weight reductions observed in the SCALE program were not associated with changes in serum creatinine.

KW - Adult

KW - Anti-Obesity Agents/adverse effects

KW - Biomarkers/blood

KW - Body Mass Index

KW - Combined Modality Therapy/adverse effects

KW - Creatinine/blood

KW - Diabetes Mellitus, Type 2/blood

KW - Diabetic Nephropathies/chemically induced

KW - Double-Blind Method

KW - Female

KW - Glomerular Filtration Rate/drug effects

KW - Glycated Hemoglobin A/analysis

KW - Humans

KW - Hypoglycemic Agents/adverse effects

KW - Kidney/drug effects

KW - Liraglutide/adverse effects

KW - Male

KW - Middle Aged

KW - Obesity/complications

KW - Prediabetic State/blood

KW - Renal Insufficiency/chemically induced

KW - Weight Loss/drug effects

U2 - 10.1016/j.jdiacomp.2017.04.003

DO - 10.1016/j.jdiacomp.2017.04.003

M3 - Journal article

C2 - 28462892

SN - 1056-8727

VL - 31

SP - 1164

EP - 1168

JO - Journal of Diabetes and its Complications

JF - Journal of Diabetes and its Complications

IS - 7

ER -

Effect of weight reductions on estimated kidney function: Post-hoc analysis of two randomized trials

Abstract

Keywords

UN SDGs

Access to Document

Fingerprint

Cite this